HD-OPM Archive
Hashtags

#paradigm

13 posts

Statins do not slow coronary calcium; severe-calcification odds hit 4.48 after 10+ years

Dec 02, 2025 · Gokhan Can ♥ 17 · 💬 41 Statins

Evidence review concluding statins reduce events and soft plaque but do not slow Agatston CAC progression, and that long-term cohorts show calcification accelerating without plateau, interpreted as plaque repair into stable scar. Trials: St. Francis (CAC unchanged, events down 33%), SALTIRE (progression 26% vs 18%) and BELLES (similar progression, ~11-14%).

JACC review: rapid plaque progression precedes rupture and LDL below 70 mg/dL halts it

Jan 02, 2026 · Gokhan Can ♥ 19 · 💬 5 Plaque, CAC & CT angiography

Summarises a 2019 JACC review arguing plaque progression is a necessary, modifiable step between subclinical atherosclerosis and MI, and that preventive strategy should shift toward imaging and aggressively treating subclinical disease. It reports data from PROSPECT, PARADIGM, GLAGOV and PESA showing progression stops at LDL <70 mg/dL and regression needs lower.

Nicola Guess: Keto-CTA plaque rose ~20 mm3 in 1 year vs ~13 mm3 over 3 years in PARADIGM

Apr 12, 2025 · Louis Nervegna ♥ 7 · 💬 8 Plaque, CAC & CT angiography

Louis shares Dr. Nicola Guess's critique of the Keto-CTA study: the abstract omitted the registered primary outcome (non-calcified plaque volume), but the figure suggests a rise of ~20 mm3 in one year in lean keto dieters. In PARADIGM, high-risk people on Western diets rose ~13 mm3 over three years (about 17 mm3 with metabolic syndrome). With no control group, the comparison suggests accelerated soft plaque growth.

Letter to JACC: Keto-CTA omitted pre-specified outcome, a 43% rise in non-calcified plaque

Apr 21, 2025 · Louis Nervegna ♥ 4 · 💬 1 Plaque, CAC & CT angiography

Louis shares a letter to the editor critiquing the Keto-CTA study of lean mass hyper-responders. It argues the primary outcome (non-calcified plaque volume) was not reported in the paper, but the lead author later shared a median increase of 18.8 mm3 (~43%), several-fold above normal annual progression and in contrast to regression seen in DISCO-CT. The 0.8% rise in percent atheroma volume also exceeds typical annual change in PARADIGM.

Keto-CTA plaque growth matched diabetics' and far exceeded high-risk statin-treated groups

Apr 16, 2025 · Louis Nervegna ♥ 4 · 💬 1 Plaque, CAC & CT angiography

Louis quotes an analysis of the Keto-CTA trial putting its plaque progression in context: median non-calcified plaque rose 18.8 mm3 in one year, comparable to type 2 diabetics (~17.4 mm3/yr), about triple PARADIGM metabolically normal people, and nearly 3x SMARTool high-risk non-statin users (6.4 mm3/yr). PAV rose 0.8% overall and 2.4% in those with CAC over 100.

Keto-CTA omitted its primary plaque outcome: median NCPV rose 18.8 mm3, 2.5x forecast

Apr 13, 2025 · Louis Nervegna ♥ 6 Plaque, CAC & CT angiography

Louis quotes Alex Leaf's critique: the Keto-CTA paper barely mentioned non-calcified plaque volume (NCPV), the primary outcome, saying only 'most participants presented with stable NCPV'. The lead author later gave a median increase of 18.8 mm3, over 2.5x the 7 mm3 predicted, comparable to metabolic syndrome over 3 years or type 2 diabetes per year, and nearly 3x SMARTool high-risk non-statin users.

Heart failure in 2026: SGLT2 inhibitors foundational, HFpEF now treatable, early GDMT

Mar 29, 2026 · Louis Nervegna ♥ 4 Heart rhythm & heart failure

A Cardiophilia summary of the latest heart failure evidence update lists several shifts: SGLT2 inhibitors are foundational across the ejection fraction spectrum, HFpEF now has options (finerenone, GLP-1 and incretin therapies), guideline therapy starts in-hospital, decongestion becomes guided by urine sodium, and devices are integrated into care.